Since KMO overactivity has been shown to contribute to the severity of AKI after IRI, AP, and AP-MODS symptoms, administering KMO inhibitors appears to be an effective strategy for managing these disorders [162,166,167]. This evidence concerns the gene KMO and acute kidney injury.